Iproteos

MainImage

100.000€

Out of 100,000.00€

investors

42

Est. ROI

124%

days left

--

Developing tomorrows drugs

Finish date: 01/12/2014 Barcelona
iproteos8

Premoney valuation

1,600,000.00€

Percentage offered

5.14%

Est. ROI

124%

Exit horizon

2016

The project

Iproteos, a company based in Barcelona (Spain), is one of the world leading companies in developing new treatments for Central Nervous System diseases such as schizophrenia, epilepsy or Parkinson.

Iproteos (www.iproteos.com) is a private biotechnology company founded as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Universitat de Barcelona (UB). The company founders are two leading Catalan scientists in the field of therapeutic peptides:

Teresa Tarragó, PhD in Biology by the UB. Research Associate at IRB and Executive MBA by ESADE, she has been leading scientific teams in the field of protein interactions and Central Nervous System (CNS) for over 15 years.

Ernest Giralt, Professor of Organic Chemistry at the UB and Head of the Chemistry and Molecular Pharmacology program at IRB Barcelona. He is considered one of the world's key-opinion leaders in the therapeutic peptide research and protein interactions. He has published over 300 articles and has received numerous awards for his outstanding scientific career.


Iproteos is currently developing new treatments for CNS diseases. Specifically, on drugs for the treatment of epilepsy, schizophrenia and Parkinson's disease.
 

A Brief Introduction to CNS and peptidomimetics as drugs ?

Treatment of CNS-related diseases is hampered by the presence of a biological barrier named blood-brain barrier (BBB) that separates the brain (where drugs perform their therapeutical effect) from the blood (where the drug is introduced and transported).
 
Biological drugs (antibodies) are too large and complex. Moreover, they are unable to cross the BBB and hence present a very low effectiveness. Alternatively, smaller molecules are generally less specific and lead to increased toxicity - and therefore, increased side effects.



Iproteos is focusing his research on the development of peptide drugs small enough to be permeable to the BBB but presenting high specificity and affinity to the protein target, while featuring a low toxicity profile.
 
After three years of research, the first drug developed by Iproteos for the treatment of schizophrenia is already in pre-clinical studies and has shown to be effective in animal models, namely mice. This stage is immediately previous to developing the drug’s use for humans.

Business opportunity

Unfortunately, CNS-related diseases are continuously increasing in developed countries where the average age is on the rise.

  • One out of 13 europeans are currently diagnosed with epilepsy, a disease that affects 60 million people worldwide.
  • It is estimated that by 2030 there will be around 9 million Parkinson’s patients diagnosed in the U.S., Europe and Japan.
  • Around 24 million people suffer from schizophrenia, and only 1 out of 5 will achieve full recovery.

 
These estimates are translated in a potential huge market for the treatment of CNS diseases:



Likewise, CNS disease market is constantly expanding and the sales are expected to continue to rise even with the appearance and generalized use of generic drugs. Specifically, the market for therapeutic peptides has also experienced sustained and steady growth in the last ten years:





 

3 - Why Iproteos?

 
Biomedical research is globalized and extremely competitive field where Iproteos owns a oustanding asset: IPRO Technology, a combination of computational and biotechnological tools developed by Iproteos Team Members aimed to speed up the peptide research process in the field of therapeutic drugs.

To obtain a therapeutic peptide, Iproteos has developed from scratch an in-house and incredibly sophisticated computational platform consisting of several software tools (Atlas, Canvas and Dante) to model and to virtually test the behavior of a given protein when interacting with a peptidic drug.

The IPRO Technology workflow is deployed as detailed below:

  • Ad hoc peptide library generation and simulation of their behavior in the presence of a protein target.
  • Selection and synthesis of the best in silico peptidic proposals based on their synthetic feasibility.
  • Peptide’s experimental evaluation against a given protein target.


 

With the deployment of IPRO Technology, Iproteos has become one of the most advanced biotechnological companies in the field of peptide drug development for CNS diseases. Moreover, Iproteos has discovered new First-in-Class treatment for such a challenging market as schizophrenia treatments.

Investment & Exit

Why do we need monetary investment?

Iproteos’ budget requirement for the first 4 years has been estimated over 1 Million €, of which roughly 0,8 M€ have been filled by private capital, shareholders and public grants.
 
We are actually looking for a new financing round of 300,000 € distributed as follows:
 

  • 100,000€ to complete the pre-clinical stage (efficacy and safety) of Schizophrenia Project (IPR019)
  • 100,000€ to perform efficacy assays in Parkinson’ animal models (IPR-19).
  • 100,000€ to complete the discovery phase of the Epilepsy’s project in order to start the pre-clinical efficacy trials..

 
The present funding campaign aims to raise 100,000 € to complete the schizophrenia project trials, which is at a very advanced stage and is expected to be the first out-licensed peptide drug. The other targets will be consecutively met in successive financing rounds.
 
These funds are intended for staff and research material only.

 

Exit strategy: How much money will investors get back? When?


Two different scenearios are considered:

  • Dividends: The first project (schizophrenia) will be ready to be out-licensed in 2016. Revenue estimates foresee the possibility of offering dividends.
  • Recapitalization: A recapitalization could be done in 2015, allowing subsidized repurchase shares.



A conservative estimate expects an internal rate of return (IRR) of 124% for 2016.

Drivers

Perfil de los impulsores del proyecto

  Teresa Tarragó,  CEO  & Founder

PhD in Biology by UB, Research Associate at IRB and Executive MBA by ESADE. she has been leading scientific teams in the field of protein interactions and Central Nervous System (CNS) for more than 15 years. She holds 2 patents and has published several articles and reviews about the field.

She has collaborated with other biotech companies, such as Farmhispania, Zyenthia Ltd, SOM Biotech and Intelligent Pharma.

 
 


 



 Ernest Giralt, Co-Founder and Chairman of Scientific Advisory Board

Professor of Organic Chemistry at the UB and Head of the Chemistry and Molecular Pharmacology program at IRB Barcelona. More than 30 years of experience in peptide synthesis and biomedical research; he is considered one of the world's key-opinion leaders in the therapeutic peptide research and protein interactions. He has been awarded the prestigious Novartis Lecturer (2011). He has published over 300 articles in high-peer reviewed journals and holds 10 patents.
 
He is a member of several scientific boards in pharmaceutical and biotechnological companies. 


 



 


 Soledad Royo, Head of Medicinal Chemistry and Intelectual Property (IP)


PhD in Chemistry by the University of Zaragoza, with extensive international research experience and multidisciplinary profile, encompassing organic and peptide chemistry and both IP and project management.
 


 


 Roger Prades, Head of Pre-clinical Development

 

PhD in Chemistry by the UB, with an interdisciplinary and extensive profile in the chemistry and molecular biology fields.
 

 

 


 Jesús Seco, Head of Computational Chemistry

 

PhD in Chemistry by UB, with extensive research experience in structure-based drug design carried out both at academia and pharmaceutical companies.



 


 Pascal Nizet
Strategy Consultant in Pharmaceutical Business Development

Professional development in the field of pharmaceutical business for over 15 years. After working more than 10 years as International Marketing Responsible for Almirall, he founded in 2008 his own consulting pharmaceutical company (Pharmaphenix). He has also been Strategic Marketing Director at Laboratorios Rubio.

He is also a member of the Directory Board at Bionure, and he is actively involved in other biomedical projects.

 

Partners & Associates

Catia Teixeira, PhD
PhD, Consultant in Neurobiology

Researcher at Columbia University, she has extensive experience in the field of behavioral neurology. More than 15 years of experience in various prestigious research institutions in the study of the molecular basis of behavioral, cognitive and psychiatric disorders.
 
 




 


J. Javier Meana, MD, PhD, Consultant in Pharmacology and Schizophrenia

Professor of Pharmacology at the University of the Vasque Country (UPV / EHU). Head of the Neuro-psychopharmacology group, he has extensive experience in pharmacology and neurobiology. In 2009 was awarded as “Best Researcher in Psychiatry” by the Spanish Society of Biological Psychiatry.




 


 

Product/Service

En un mercado globalizado e increíblemente competitivo como el de la investigación biomédica, Iproteos cuenta con una ventaja competitiva clave: la exclusiva tecnología IPRO, una combinación de herramientas informáticas y biotecnológicas desarrolladas por el propio equipo de investigación de Iproteos que permite acelerar enormemente los procesos de investigación sobre péptidos.

Para lograr esto se ha desarrollado software específicamente diseñado para generar, modelizar y testear proteínas virtuales: los programas Atlas, Canvas y Dante, unas herramientas de investigación biológica asombrosamente complejas y sofisticadas.

El modelo es el siguiente:

  • Generación de péptidos “virtuales” y simulación de sus características
  • Selección de los péptidos con mejores resultados
  • Preparación en el laboratorio de los péptidos “candidatos”
  • Investigación y ensayo de esos péptidos


 

Gracias a esto, Iproteos es a día de hoy una de las compañías biotecnológicas más avanzadas en la investigación de fármacos peptídicos para las enfermedades del sistema nervioso central, permitiéndole desarrollar vías de tratamiento First-in-Class para enfermedades con un mercado tan amplio como la esquizofrenia.

Market

 

Iproteos no pretende llevar todo el proceso de desarrollo y fabricación de los fármacos que investiga. Después de todo, un nuevo fármaco puede llegar a tardar diez años en pasar del descubrimiento a la comercialización.

En lugar de eso, Iproteos descubre y desarrolla los fármacos hasta la fase preclínica, y a continuación vende la licencia de éstos a compañías farmacéuticas que continuarán con la investigación (con o sin la participación de Iproteos). La venta de una única licencia para fármacos en ese estado de desarrollo suele rondar los 15 millones de euros - aunque esa cantidad variará en función del estado de desarrollo del fármaco en el momento de licenciarlo.

Por tanto, Iproteos utiliza su potentísima base tecnológica de investigación para descubrir, evaluar y desarrollar nuevos fármacos, cuyas licencias vende a otras compañías, en un ciclo que dura entre dos y cuatro años.

Marketing & sales

 

La venta de las licencias que se desarrollan se realiza sin marketing; los clientes de Iproteos son compañías farmacéuticas de tamaño mediano y grande, y a ese nivel los contactos comerciales se realizan directamente en persona – por parte de Iproteos, Teresa Tarragó, CEO, investigadora jefe y MBA Executive por ESADE es la encargada de contactar con los responsables de desarrollo de las grandes empresas farmacéuticas.



En estos momentos ya existen negociaciones directas para la venta de una de las licencias investigadas.

 

 

Roadmap

La competencia de Iproteos está descrita en detalle en un documento aparte, ya que el análisis de todos los factores implicados es bastante complejo (distintos estados de desarrollo, distintos productos, distintos tipos de tratamiento, etc...).

En general, se trata de un mercado en el que la competencia es global, y en el que Iproteos cuenta con algunas ventajas clave:

  • La tecnología IPRO está permitiendo procesos de investigación más rápidos y efectivos, gracias a la modelización informática de procesos biológicos. En suma, es más rápido probar el comportamiento de 20.000 péptidos en una simulación informática que sintetizarlos todas y probarlos en vivo.
  • El fármaco desarrollado para el tratamiento de la esquizofrenia es el primer y único fármaco destinado a curar los síntomas cognitivos de la enfermedad.
  • Iproteos se especializa en el desarrollo de péptidos, un tipo de fármaco de alta especificidad, baja toxicidad y alta eficacia, un nicho relativamente poco cubierto.

En resumen, Iproteos presenta estas dos ventajas claras respecto a sus competidores:

  • es más eficaz y rápida desarrollando fármacos
  • trabaja con fármacos más eficientes  y seguros

No obstante, recomendamos leer el análisis de la competencia con un poco más de detenimiento. Es una lectura algo científica pero muestra claramente la privilegiada posición de Iproteos en el mercado. 

Investment details

Detalles sobre el capital solicitado

Iproteos está en un proceso de ampliación de capital para financiar 300.000 euros mediante la emisión global de 88.067 nuevas participaciones por un 18% de la compañía.

A través de Creoentuproyecto se lanza una campaña de Financiación Participativa por 25.162 participaciones - 100.000 euros, o un 5,14% de la compañía.

 

Exit details

Condiciones que se ofrecen

Los nuevos socios adquieren Participaciones Sociales sin derecho a voto pero con:

Derecho de acompañamiento: se garantiza a los nuevos socios que en caso de que algún Socio Mayoritario de Iproteos reciba una oferta por al menos 1'5 veces el valor nominal de estas participaciones podrán vender las suyas también si lo desean

Derecho de arrastre: en caso de que Iproteos reciba una oferta de compra por al menos 2 veces el valor de las participaciones de esta operación, los nuevos socios estarán obligados a vender sus participaciones.